Posters

Once-daily valbenazine is approved for tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD). Cohen’s d for valbenazine in TD was calculated using data from KINECT® 3 (NCT02274558), a 6-week, fixed-dose study (valbenazine 40 or 80 mg) with efficacy assessed based on change from baseline (CFB) in the Abnormal Involuntary Movement Scale (AIMS) total score.

Tardive dyskinesia (TD) significantly impacts quality of life (QoL) beyond movement symptoms. A web-based survey and chart extraction among US physicians, nurse practitioners, and physician assistants characterized TD burden and improvement following valbenazine treatment.

Tardive dyskinesia (TD) is a potentially disabling involuntary movement disorder due to dopamine receptor-blocking agent exposure and can impair physical, psychological, functional, and socio-emotional well-being. The 11-item Tardive Dyskinesia Impact Scale (TDIS) is a reliable, valid, TD-specific, patient reported outcome measure evaluating TD symptom impact over the previous 7 days. 

Tardive dyskinesia (TD) is a movement disorder associated with prolonged exposure to dopamine receptor blocking agents that can significantly impact one’s quality of life (QoL). A phase 4 study (NCT03891862) assessed persistence of effects of valbenazine (VBZ), a vesicular monoamine transporter 2 inhibitor approved for treatment of TD.

Deutetrabenazine demonstrated clinically significant improvements in Abnormal Involuntary Movement Scale (AIMS) scores in 12-week pivotal tardive dyskinesia (TD) trials (ARM-TD [NCT02195700]/AIM-TD [NCT02291861]). African descent has been identified as a risk factor for TD. This post hoc analysis assessed long-term efficacy and safety of deutetrabenazine by racial subgroups.